R&D Looking to gene therapy for ocular diseases, with Lance Bald... Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
Digital Creating what nature has not from AI and computational molec... Kashif Sadiq, founder and CEO of DenovAI Biotech discusses harnessing the power of artificial intelligence and computational molecular biophysics.
Digital On collaboration, computational chemistry, and cutting-edge ... Dr Olga Nissan, vice president of business development at Evogene discusses collaboration with Google Cloud & generative design of small molecules.
R&D Making AI work where it matters, with Rob DiCicco Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.
R&D Treating genetic disease at scale with tRNA, with Michelle W... Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.
R&D AI in clinical development & ‘white space’, with Andrew Mack... Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.